Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 6, 2011, Pages 992-1000

  Etame, Arnold B ^a   Smith, Christian A ^a   Chan, Warren C W ^b   Rutka, James T ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Brain microvasculature; Brain tumors; Gold nanoparticles; Permeation; Polyethylene glycol

Indexed keywords

BLOOD-BRAIN BARRIER; BLOOD-BRAIN BARRIER MODELS; BRAIN TUMORS; CORE PARTICLES; CORE SIZE; ENHANCED PERMEATION AND RETENTIONS; FUNCTIONALIZED; GOLD NANOPARTICLE; GOLD NANOPARTICLES; GOLD NPS; IN-VITRO; MALIGNANT TUMORS; MICRO-VASCULATURE; MODEL SYSTEM; PASSIVE TARGETING; PERMEATION PROPERTIES; POTENTIAL APPLICATIONS; TUMOR MICROVASCULATURE;

BLOOD; BRAIN; CHAIN LENGTH; GLYCOLS; GOLD; MOLECULAR WEIGHT; NANOPARTICLES; PARTICLE SIZE; PERMEATION; POLYETHYLENE GLYCOLS; POLYETHYLENES; THERMOPLASTICS;

TUMORS;

GOLD NANOPARTICLE; MACROGOL;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN MICROVASCULATURE; BRAIN TUMOR; DRUG DESIGN; DRUG PENETRATION; DRUG STABILITY; DRUG SYNTHESIS; DRUG TRANSPORT; MICROVASCULATURE; MOLECULAR WEIGHT; PARTICLE SIZE;

BLOOD-BRAIN BARRIER; BRAIN; GOLD; HUMANS; MICROVESSELS; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; POLYETHYLENE GLYCOLS;

EID: 82255186416     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.04.004     Document Type: Article

References (42)

1. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001, 41:189-207.
2. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 2007, 15:457-464.
3. Schneider S.W., Ludwig T., Tatenhorst L., Braune S., Oberleithner H., Senner V., et al. Glioblastoma cells release factors that disrupt blood-brain barrier features. Acta Neuropathol 2004, 107:272-276.
4. Criscuolo G.R. The genesis of peritumoral vasogenic brain edema and tumor cysts: a hypothetical role for tumor-derived vascular permeability factor. Yale J Biol Med 1993, 66:277-314.
5. Strugar J., Rothbart D., Harrington W., Criscuolo G.R. Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis. J Neurosurg 1994, 81:560-566.
6. Gerstner E.R., Duda D.G., di Tomaso E., Ryg P.A., Loeffler J.S., Sorensen A.G., et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 2009, 6:229-236.
7. Stummer W. Mechanisms of tumor-related brain edema. Neurosurg Focus 2007, 22:E8.
8. Connor E.E., Mwamuka J., Gole A., Murphy C.J., Wyatt M.D. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 2005, 1:325-327.
9. Male K.B., Lachance B., Hrapovic S., Sunahara G., Luong J.H. Assessment of cytotoxicity of quantum dots and gold nanoparticles using cell-based impedance spectroscopy. Anal Chem 2008, 80:5487-5493.
10. Paciotti G.F., Myer L., Weinreich D., Goia D., Pavel N., McLaughlin R.E., et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 2004, 11:169-183.
11. Hainfeld J.F., Slatkin D.N., Smilowitz H.M. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol 2004, 49:N309-N315.
12. Mukherjee P., Bhattacharya R., Wang P., Wang L., Basu S., Nagy J.A., et al. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res 2005, 11:3530-3534.
13. Brown S.D., Nativo P., Smith J.A., Stirling D., Edwards P.R., Venugopal B., et al. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc 2010, 132:4678-4684.
14. Cheng Y., Samia A., Meyers J.D., Panagopoulos I., Fei B., Burda C. Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. J Am Chem Soc 2008, 130:10643-10647.
15. Hirsch L.R., Stafford R.J., Bankson J.A., Sershen S.R., Rivera B., Price R.E., et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A 2003, 100:13549-13554.
16. Visaria R.K., Griffin R.J., Williams B.W., Ebbini E.S., Paciotti G.F., Song C.W., et al. Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-alpha delivery. Mol Cancer Ther 2006, 5:1014-1020.
17. Huang X., Jain P.K., El-Sayed I.H., El-Sayed M.A. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med Sci 2008, 23:217-228.
18. Bernardi R.J., Lowery A.R., Thompson P.A., Blaney S.M., West J.L. Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines. J Neurooncol 2008, 86:165-172.
19. Schwartz J.A., Shetty A.M., Price R.E., Stafford R.J., Wang J.C., Uthamanthil R.K., et al. Feasibility study of particle-assisted laser ablation of brain tumors in orthotopic canine model. Cancer Res 2009, 69:1659-1667.
20. Libutti S.K., Paciotti G.F., Byrnes A.A., Alexander H.R., Gannon W.E., Walker M., et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res. 2010, 16:6139-6149.
21. Veiseh O., Sun C., Gunn J., Kohler N., Gabikian P., Lee D., et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett 2005, 5:1003-1008.
22. Kohler N., Fryxell G.E., Zhang M. A bifunctional poly(ethylene glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. J Am Chem Soc 2004, 126:7206-7211.
23. Cai W., Shin D.W., Chen K., Gheysens O., Cao Q., Wang S.X., et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett 2006, 6:669-676.
24. Susumu K., Uyeda H.T., Medintz I.L., Pons T., Delehanty J.B., Mattoussi H. Enhancing the stability and biological functionalities of quantum dots via compact multifunctional ligands. J Am Chem Soc 2007, 129:13987-13996.
25. Liu Z., Winters M., Holodniy M. Dai H. siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew Chem Int Edn Engl 2007, 46:2023-2027.
26. Dixit V., Van den Bossche J., Sherman D.M., Thompson D.H., Andres R.P. Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells. Bioconjug Chem 2006, 17:603-609.
27. Perrault S.D., Walkey C., Jennings T., Fischer H.C., Chan W.C. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 2009, 9:1909-1915.
28. Sonavane G., Tomoda K., Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces 2008, 66:274-280.
29. De Jong W.H., Hagens W.I., Krystek P., Burger M.C., Sips A.J., Geertsma R.E. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008, 29:1912-1919.
30. Frens G. Controlled nucleation for the regulation of the particle size in monodisperse gold suspensions. Nature 1973, 241:20-22.
31. Garberg P., Ball M., Borg N., Cecchelli R., Fenart L., Hurst R.D., et al. In vitro models for the blood-brain barrier. Toxicol in Vitro 2005, 19:299-334.
32. Culot M., Lundquist S., Vanuxeem D., Nion S., Landry C., Delplace Y., et al. An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening. Toxicol in Vitro 2008, 22:799-811.
33. Stanness K.A., Westrum L.E., Fornaciari E., Mascagni P., Nelson J.A., Stenglein S.G., et al. Morphological and functional characterization of an in vitro blood-brain barrier model. Brain Res 1997, 771:329-342.
34. Nakagawa S., Deli M.A., Kawaguchi H., Shimizudani T., Shimono T., Kittel A., et al. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int 2009, 54:253-263.
35. Romberg B., Hennink W.E., Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm Res 2008, 25:55-71.
36. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001, 53:283-318.
37. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006, 307:93-102.
38. Alkilany A.M., Nagaria P.K., Hexel C.R., Shaw T.J., Murphy C.J., Wyatt M.D. Cellular uptake and cytotoxicity of gold nanorods: molecular origin of cytotoxicity and surface effects. Small 2009, 5:701-708.
39. Chithrani B.D., Chan W.C. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett 2007, 7:1542-1550.
40. Chithrani B.D., Ghazani A.A., Chan W.C. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006, 6:662-668.
41. Semmler-Behnke M., Kreyling W.G., Lipka J., Fertsch S., Wenk A., Takenaka S., et al. Biodistribution of 1.4- and 18-nm gold particles in rats. Small 2008, 4:2108-2111.
42. Terentyuk G.S., Maslyakova G.N., Suleymanova L.V., Khlebtsov B.N., Kogan B.Y., Akchurin G.G., et al. Circulation and distribution of gold nanoparticles and induced alterations of tissue morphology at intravenous particle delivery. J Biophotonics 2009, 2:292-302.